

Resolving Barriers to a Successful Pregnancy

Uterine Lining Dysfunction & Progesterone Resistance

“To be a successful farmer one must first know the nature of the soil.”

Xenophon, Ancient Greek philosopher
Circa 430-354 BC



ReceptivaDx
Endometrial Biopsy Analysis

What is ReceptivaDx™ ?

ReceptivaDx measures BCL6, an inflammatory marker not normally present during the window of implantation.

BCL6 identifies uterine lining dysfunction and progesterone resistance, two key factors that may impact the ability for women to become pregnant and maintain pregnancy.

Women who test positive and are appropriately treated can expect a 60% chance of achieving pregnancy in their next transfer attempt.

A negative result offers reassurance that the uterine lining is not likely a factor in the patient's infertility.



**93% sensitivity and
96% specificity for
endometriosis**



**Immunohistochemistry
analysis**




**Additional marker
options include CD138
for endometritis**

Candidates for ReceptivaDx Testing

- Women with unexplained infertility
- Women with history of implantation failure
- Women experiencing pregnancy loss
- Women with limited embryo reserves
- Women who cannot afford IVF or those with limited fertility coverage

The Science Behind ReceptivaDx

Treatment Outcomes For Positive BCL6 Patients Hormone Suppression vs. Laparoscopy



Likes et al., J. Assisted Reproduction and Genetics
January 2019

®

Published Clinical Papers Supporting the Role of BCL6 in Unexplained Infertility

Women with a positive BCL6 result and left untreated are 5 times more likely to fail their next IVF transfer than women testing negative.

Fertility and Sterility
December 2017 Almquist, et al.

Women with unexplained recurrent pregnancy loss (uRPL), defined as two or more consecutive losses, exhibit high levels of BCL6.

Human Reproduction Open
October 2019 Fox, et al.

Overexpression of SIRT1/BCL6 contributes to the pathogenesis of endometriosis and progesterone resistance resulting in pain, infertility and pregnancy loss.

Scientific Reports
July 2017 Yoo, et al.

Quotes

“ *ReceptivaDx™ provides unique information for our patients with unexplained infertility, failed IVF history and those with recurrent pregnancy loss. In the past, so many of these patients would simply give up. The test has made a significant difference for our practice.* ”

Sunny Jun, M.D. CCRM San Francisco
Menlo Park, CA

“ *When a patient has high quality, genetically screened embryos and still can't become pregnant, ReceptivaDx has provided answers for our patients when we had no other known explanations for their transfer failure history.* ”

Lora Shahine, M.D Pacific NW Fertility
Seattle, WA

“ *Endometriosis/uterine receptivity defects are common and in this 'no laparoscopy' era, ReceptivaDx is essential for diagnosis and treatment planning.* ”

Alex Steinleitner, M.D. Simple IVF Centers Artisan Medical Solutions
San Luis Obispo, CA

“ *ReceptivaDx has given me insight into previously unexplained infertility and failed IVF, especially after PGT, along with treatment options for my patients.* ”

Dr. Laurence Jacobs, M.D. Fertility Centers of Illinois
Chicago and Buffalo Grove, IL

Fertility Center Challenges

Up to 40 to 50% of patients are still failing to become pregnant or maintain pregnancy after transfer of normal (PGT-A tested) embryos and optimized transfer timing.

Published data combined with over a thousand ReceptivaDx patient test results demonstrate the importance of uncovering asymptomatic uterine lining dysfunction caused by inflammation.



“Common sense tells us that endometriosis is a major cause of subfertility, but women undergoing IVF are rarely diagnosed with the disease before treatment. Laparoscopy has fallen out of favor but ReceptivaDx provides an opportunity for couples to better understand the basis of their infertility and will provide more options and higher success rates.”

Bruce Lessey, MD, Ph.D.
Wake Forest Baptist Health, Winston-Salem NC

Ordering Information

Sample Requirements

An endometrial biopsy is collected during the window of implantation in either a natural cycle or controlled “mock cycle.” Accurate biopsy timing is important to the quality of results.



Natural Cycle



Mock Cycle

Collection Kits/Test Request Forms

Available through customer service at (800) 795-5385. Overnight shipping material and prepaid shipping labels are provided at no cost as part of our ReceptivaDx Collection Kit. International customers must secure shipment to the US at their own expense. Contact us via email at info@receptivadx.com for international shipping instructions.

Test Fees and Payment Information

ReceptivaDx- \$690 USD. Pricing covers pathology review and BCL6 analysis. CD138 marker for endometritis can be added for an additional \$125. Payment must be submitted at time of sample submission. All major credit cards accepted. Cicero Diagnostics does not bill or contract with insurance plans. A detailed receipt is provided to patients for submission to insurance payor or healthcare spending accounts.

Test Results

Available in 5-6 business days.

Contact Information

 receptivadx.com  info@receptivadx.com  (800)795-5385

ReceptivaDx is exclusively offered through Cicero Diagnostics Inc.